Sign In
Buy INRLF
$2.74
+0.160 (+6.20%)
At Close: Jun 03, 2026
Valneva SE (VALN) Q1 2026 Earnings Call Transcript
01:01pm, Wednesday, 13'th May 2026
Valneva SE (VALN) Q1 2026 Earnings Call Transcript
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon Regulated market of Euronext Paris - Compartment B
Declaration of shares and voting rights of Valneva SE – March 2026
02:30am, Friday, 03'rd Apr 2026
VALNEVA Declaration of shares and voting rights March 31, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot S
The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive
10:35am, Monday, 23'rd Mar 2026
The Phase 3 VALOR trial results showed that fewer Lyme disease cases were accrued than anticipated, and the primary endpoint was not met in the first analysis.
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
07:02am, Monday, 23'rd Mar 2026
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.
Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
06:47am, Monday, 23'rd Mar 2026
U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
06:45am, Monday, 23'rd Mar 2026
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for
Valneva SE (VALN) Q4 2025 Earnings Call Transcript
02:12pm, Wednesday, 18'th Mar 2026
Valneva SE (VALN) Q4 2025 Earnings Call Transcript
VALNEVA Declaration of shares and voting rights: February 28, 2026
12:00pm, Friday, 06'th Mar 2026
VALNEVA Declaration of shares and voting rights February 28, 2026 __________________________________________________________________________________________ Company name: VALNEVARegistered office: Îl
VALNEVA Declaration of shares and voting rights: January 31, 2026
02:30am, Friday, 06'th Feb 2026
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon.
Valneva withdraws application for standard US approval of its chikungunya shot
02:00pm, Monday, 19'th Jan 2026
French drugmaker Valneva said on Monday it has voluntarily withdrawn its application seeking standard approval of its chikungunya vaccine in the United States after the FDA suspended the shot's licens
Valneva SE - Declaration of voting rights - December 2025
12:30pm, Thursday, 08'th Jan 2026
Registered office: Îlot Saint Joseph Bureaux Convergence – 12T Quai Perrache – 69002 Lyon
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
11:45am, Wednesday, 31'st Dec 2025
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group
VALNEVA Declaration of shares and voting rights: November 30, 2025
12:34pm, Friday, 05'th Dec 2025
Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France).
